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Pharmacy News
‘Warfarin’ – High Alert Medication Policy
Update

Preamble
Oral anticoagulation with warfarin is a challenging
task for health care providers around the world.
Due to narrow therapeutic index and less predictable pharmacokinetics, its use should be abided by
strict safety measures. These include safe prescribing, monitoring, patient education and regular follow ups. The important monitoring aspects are
evaluation for active bleeding, bleeding tendencies and laboratory parameters such as prothrombin time/ international normalized ration.
Our Scenario: Appreciating the potential risk
to the patients, Pharmacy and Therapeutics
Committee (P and TC) of AKUH has categorised
Warfarin as High Alert Medication and developed
a Prescribing and Monitoring Guideline along with
Patient’s Guide and Record Book.
Salient features of the guidelines are given below:
Correct Patient:
• Patient should be identified properly with two
identifiers before prescribing, dispensing and
administration.
Prescribing and Monitoring:
• Verbal orders are not allowed for Warfarin.
• All the prescribing and monitoring shall be
guided by the approved guidelines.
• Order shall be complete, correct and include
all the necessary parameters.
• Baseline INR should be checked before
ordering and repeated at suitable intervals to
ensure proper dosing.
• Target INR value is set and known to all care
providers in order to ensure proper dose
adjustment and monitoring.
• Proper assessment for side effects is carried
out (esp. bleeding) at suitable intervals.
• Order should be reviewed every 24 hours or
upon the availability of recent lab values.
Dispensing and Patient Education:
• Warfarin will be dispensed from pharmacy
against a valid physician order.
• Dispensed dose will be labeled properly with
complete dosing information.
• Medication related education is provided to
patient/family upon discharge and on OPD
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refills to ensure safe use of this drug.
Guidelines Also Mention:
• need and rationale of loading dose
• maintenance dose and dose adjustments
• target INRs for different indications
• duration of therapy
• common and important drug-to-drug and drugfood interactions
• reversal before surgery
• risk factors for bleeding
• management of moderate and severe bleeding
• head to toe assessment for side effects
Details are available in High Alert Medications
Policy (annexure) available at :
http://intranet/pharmacy/pdf/QA018.pdf

Rational use of Antibiotics 2011 – Snapshot
Preamble
Antibiotic Subcommittee (ABSC) of AKUH has
selected six broad spectrum and costly
antibiotics that are considered as the last resort for
multi-drug resistant microorganisms. Hence, their
usage is guided by the approved protocol for
prescribing. Adherence to set criteria is also
periodically monitored to ensure their rational use.
Six restricted antibiotics are imipenem,
meropenem, vancomycin, polymyxin B, piperacillin/
tazobactam and linezolid.

Methodology for Drug Utilisation Reviews (DURs)
A representative sample of patients was taken
who were administered the restricted antibiotics.
Sample was based on the volume of consumption of antibiotics specialty wise. Each patient was
assessed against the criteria of restricted antibiotic
usage, approved by the Antibiotic Subcommittee
(ABSC) of the Hospital. Results are plotted as either
compliance or non-compliance to the criteria of the
usage. The data is presented in the ABSC.
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Major Non-Compliance to the Approved Criteria of Restricted Antibiotics in Year 2011:
S#

Antibiotic

Concern

Improvement required in

•
•

cultures were not sent prior to start of the therapy
prolonged empiric therapy

Paediatrics
Medicine

•
•

cultures were not sent prior to start of the therapy
based on cultures, on-time de-escalation was not
carried out

Surgery
Medicine

•
3. Vancomycin •
•

cultures were not sent prior to start of the therapy
on-time de-escalation not done based on C/S
levels were not monitored properly

Medicine
Surgery
Paediatrics

•
•

empiric polymyxin upon admission
cultures were not suggestive of multiple antibiotic
resistant organisms (MARO)

Surgery

Piperacillin/ •
Tazobactam •

cultures were not sent prior to start of the therapy
duplication with other penicillins

Emergency
Surgery

•

unclear indication for linezolid, prior infectious disease approval was not taken
duplication with vancomycin

Surgery

1. Meropenem

2.

Imipenem

4.

5.

Polymyxin

6.

Linezolid

•

What can you do to help?
Clinicians should focus on the major non-compliance factors and attempts should be made to
abide the use of restricted antibiotics against the
approved criteria of the Hospital.

For complete information on the prescribing
and monitoring protocol of these antibiotics,
faculty and staff can refer to the pocket Antibiotic
Guideline or the online version at :
http://intranet/pharmacy/Antibiotic_GL_completebook.pdf

Pharmacist Interventions – Curbing Potential Prescribing Errors
According to the patient safety recommendations
worldwide and JCIA standards, review of prescription by a pharmacist is an important step to prevent
any medication error at the time of prescribing. It is
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also a tool to prevent serious medication errors.
The 2011 snapshot of pharmacists’ interventions to
provide care to a more acceptable level:
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Reporting Adverse Drug Reactions:
Literature suggests that Adverse Drug Reactions
(ADRs) account for 4-6 per cent morbidity and
0.15 per cent mortality in a given population. It is
important for patient safety perspective to identify
and report the ADRs. To report an ADR, browse the
online ADR reporting form;
http://intranet/pharmacy/adrrf.htm
FDA Safety Updates and Alerts - 2011
Drug

Updates
Treatment during pregnancy (third trimester) imposes potential
Antipsychotics
February risk for abnormal muscle movements (extrapyramidal signs or EPS)
and withdrawal symptoms in newborns.
Proton Pump Inhibitors
March
Hypomagnesemia can be associated with long-term use.
Increased risk of development of cleft lip and/or cleft palate (oral
Topiramate
March
clefts) in infants of women treated with topiramate during pregnancy.
Associated with the risk of cardiovascular events (including heart
Rosiglitazone
April
attack and stroke).
Angiotensin Receptor
Use of ARBs may be associated with a small increased risk of canJune
Blockers
cer. FDA will provide the information as the review is completed.
Increased risk of certain cardiovascular adverse events in patients
Varenicline
June
who have cardiovascular disease.
In patients with chronic kidney disease, it increases the risk of seriEpoetin alfa
June
ous cardiovascular events such as heart attack or stroke.
Risk of impaired cognitive development in children exposed to valValproate Product
June
proate products In-Utero (during pregnancy).
Use of the highest approved dose of simvastatin (80 mg) should be
Simvastatin
June
limited because of increased risk of myopathy.
Use of oral bisphosphonate drugs is associated with an increased
Oral Bisphosphonates
July
risk of cancer of the esophagus. FDA will provide the update when
more information is available.
Citalopram
August
Abnormal heart rhythms are associated with high doses.
Use of long-term, high dose fluconazole during pregnancy (first
Fluconazole
August
trimester) may be associated with birth defects in infants.
It is contraindicated in patients with creatinine clearance less than
Zoledronic acid
September
35 ml/min or in patients with evidence of acute renal impairment.
Ondansetron may increase the risk of abnormal heart rhythm,
Ondansetron
September
including torsade de pointes.
Serious CNS reactions are reported when it is given with psychiatric
Methylene Blue
October
medications that interfere the serotonin system of the brain.
Serious CNS reactions are reported when it is given with psychiatric
Linezolid
October
medications that interfere the serotonin system of the brain.
Has potential risk of persistent pulmonary hypertension of the
SSRIs’
December
newborn when used during pregnancy.

Source: www.fda.gov
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